Key result
Platelets from 4 patients with XLA had markedly reduced or no aggregation responses to activation via GPVI and FcγRIIa, and BTK inhibition correlated with reduced aggregation.
Why the study?
The full range of effects of BTK inhibitors on platelet function is incomplete, particularly their role in signaling via PEAR1, a receptor linked to thrombotic cardiovascular disease.
Do Bruton tyrosine kinase inhibitors reduce platelet aggregation mediated by FcγRIIa, GPVI, and PEAR1 in human platelets?
Population
Platelets from control subjects and 4 patients with XLA
Comparison
BTK inhibitors of varying specificity vs control
Design
In vitro laboratory study
Authors
Loading...
BTKi may safely target FcγRIIa-driven thrombosis without bleeding risk; leaves open need for clinical trials.
Do Bruton tyrosine kinase inhibitors reduce platelet aggregation mediated by FcγRIIa, GPVI, and PEAR1 in human platelets?
BTK plays an important role in platelet signaling via FcγRIIa, GPVI, and PEAR1, suggesting highly specific BTK inhibitors could serve as novel antithrombotic therapies.
Kartika et al. (2026) studied X-linked agammaglobulinemia (XLA) (n=4). Bruton tyrosine kinase (BTK) inhibitors vs. Control platelets was evaluated on Platelet aggregation initiated through FcγRIIa, GPVI, PEAR1, and other receptors. Platelets from 4 patients with XLA had markedly reduced or no aggregation responses to activation via GPVI and FcγRIIa, and BTK inhibition correlated with reduced aggregation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: